Histone 2A Family Member J Drives Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most aggressive brain tumor and has a poor prognosis and is poorly sensitive to radiotherapy or temozolomide (TMZ) chemotherapy. Therefore, identifying new biomarkers to predict therapeutic responses of GBM is urgently needed. By using The Cancer Genome Atlas (TC...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Lee, Hsun-Hua, Lin, Che-Hsuan, Lin, Hui-Yu, Kuei, Chia-Hao, Zheng, Jing-Quan, Wang, Yuan-Hung, Lu, Long-Sheng, Lee, Fei-Peng, Hu, Chaur-Jong, Wu, Dean, Lin, Yuan-Feng
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016639/
https://ncbi.nlm.nih.gov/pubmed/31906036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010098
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares